Biotech Catalyst In May
The start of the new month for new opportunity to trade and invest. For the biotech enthusiast, May is a month full of catalyst events to be on the lookout. There are multiples FDA Prescription Drug User Fee Act (PDUFA) dates, Advisory Committee (Adcom) dates, and multiples biotech Phase 2 and 3 data.
- Seattle Genetics Inc (SGEN)- May 1st
- Portola Pharmaceuticals Inc (PTLA)- May 4
- Dova Pharmaceuticals Inc (DOVA)- May 21
- Recro Pharma Inc (REPH)- May 26
- Amgen Inc (AMGN)- May 28
- TherapeuticsMD Inc (TXMD) May 29
- Achaogen Inc (AKAO)- May 2
- Lipcine Inc (LPCN)- May 8
- Akcea Therapeutics Inc and Ionis Pharmaceuticals (IONS)- May 10
- INSYS Therapeutics Inc (INSY)- May 22.
For more info, see our Calendar events https://www.tradersfish.com/Calendar/event
In addition, there are multiples biotech Phase 2 and 3 data to be in May or later this Q2. Here are some ideas:
- Aveo Pharmaceuticals Inc (AVEO)- Phase 3 TIVO-3
- Cara Therapeutics Inc (CARA) - Phase 3 CR845
- CTi Biopharma Corp (CTIC)- Phase 3
- Global Blood Therapeutics Inc (GBT)- Phase 2
- Nabriva Therapeutics PLC (NBRV). Phase 3
- Strongbridge Biopharma Plc (SBBP)(Phase 3
For a complete list of Q2 biotech data, see our link tab https://www.tradersfish.com/Biotechnology_formula/upcomingdata
To help investors with biotech data results, our #BiotechCalculator has 83% right on predicting data results. You can sign up to our site and try it out. Here is the blog for, "Biotech Upcoming Data and #BiotechCalculator Success" https://www.tradersfish.com/blog/biotech-upcoming-data-biotechcalculator
An example how to input data into the #BiotechCalculator. Global Blood Therapeutics Inc (GBT) Phase 2 to be out this month or this quarter.
Disease Area: Hematology
Market Cap: $1 billion- above
Speculation from our unique statistics formula that this data will be positive.
To use Biotech Success Speculation Probability https://www.tradersfish.com/Biotechnology_formula
All things considered, these are ideas and opinion only. You must do your own due diligence. The stock market is risky in general and biotech sector is at the top of high risk. Always know what you own. Thanks for reading, best of luck.